Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04617522
Title Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan-hziy in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Gilead Sciences
Age Groups: senior | adult
Covered Countries USA | FRA

No variant requirements are available.